Altshuler Shaham’s Vanda Pharmaceuticals VNDA Stock Holding History

Altshuler Shaham’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,451	Closed	-$18.1K	–	463
2022 Q4	$18.1K	Buy	+2,451	New	+$23.9K	﹤0.01%	370
2021 Q3	–	Sell	-5,811	Closed	-$125K	–	672
2021 Q2	$125K	Buy	5,811 +3,632	+167%	+$65K	﹤0.01%	290
2021 Q1	$33K	Buy	+2,179	New	+$35.3K	﹤0.01%	354

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Altshuler Shaham's VNDA Position: Q1 2023 in Review

Altshuler Shaham sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 2,451 shares — an estimated $18.1K sold.

Altshuler Shaham first reported a position in VNDA in Q1 2021 and held it in 3 quarters. The position peaked at $125K in Q2 2021. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Altshuler Shaham reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Altshuler Shaham sold 2,451 Vanda Pharmaceuticals shares in Q1 2023, an estimated $18.1K.
Altshuler Shaham first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Altshuler Shaham's Vanda Pharmaceuticals position peaked at $125K in Q2 2021.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Altshuler Shaham's 13F filing for Q1 2023, filed 9 May 2023.